Subscribe to RSS
DOI: 10.1055/s-0032-1306421
Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research
Publication History
Publication Date:
13 March 2012 (online)
Abstract
Nonalcoholic fatty liver disease (NAFLD) results in histologically complex specific and nonspecific injury patterns. In clinical research of NAFLD, the liver biopsy evaluation provides a wealth of information on the architectural arrangement and severity of a variety of histologic changes, including steatosis, inflammation, cellular injury, and fibrosis. This information is summarized as an overall diagnostic category, such steatosis or steatohepatitis and the severity of the injury can be graded and staged. Histopathologic disease classification in NAFLD is related to but separate from evaluation of individual histologic lesions. The patient population under study may affect the prevalence of histologic findings and in particular, pediatric patients with NAFLD may show a higher prevalence of zone 1 steatosis and periportal fibrosis as compared with adult populations. For the purposes of clinical research, it is important to provide the pathologist with biopsies that are adequate to classify the disease process as well as to grade and stage the changes. A current understanding of NAFLD pathologic classification, as well as nuances of grading and staging, is presented in this review.
-
References
- 1 Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82 (7) 650-654
- 2 Anty R, Iannelli A, Patouraux S , et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32 (11–12) 1315-1322
- 3 Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45 (4) 600-606
- 4 Xanthakos S, Miles L, Bucuvalas J, Daniels S, Garcia V, Inge T. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4 (2) 226-232
- 5 Kleiner DE, Brunt EM, Van Natta M , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6) 1313-1321
- 6 Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15 (4) 246-258
- 7 Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A ; NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008; 48 (5) 829-834
- 8 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (7) 434-438
- 9 Zimmerman HJ, MacMurray FG, Rappaport H, Alpert LK. Studies on the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin sensitivity. J Lab Clin Med 1950; 36 (6) 922-928
- 10 Zimmerman HJ, MacMurray FG, Rapparport H, Alpert LK. Studies of the liver in diabetes mellitus. I. Structural and functional abnormalities. J Lab Clin Med 1950; 36 (6) 912-921
- 11 Omary MB, Ku NO, Strnad P, Hanada S. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 2009; 119 (7) 1794-1805
- 12 Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48 (5) 821-828
- 13 Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD. Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol 2011; 35 (9) 1400-1404
- 14 Neuschwander-Tetri BA, Clark JM, Bass NM , et al; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52 (3) 913-924
- 15 Sanyal AJ, Brunt EM, Kleiner DE , et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54 (1) 344-353
- 16 Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J ; Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008; 135 (6) 1961-1971 , e2
- 17 Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95 (4) 1056-1062
- 18 Schwimmer JB, Behling C, Newbury R , et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42 (3) 641-649
- 19 Patton HM, Yates K, Unalp-Arida A , et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010; 105 (9) 2093-2102
- 20 Carter-Kent C, Yerian LM, Brunt EM , et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50 (4) 1113-1120
- 21 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD ; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49 (3) 1017-1044
- 22 Ratziu V, Charlotte F, Heurtier A , et al; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128 (7) 1898-1906
- 23 Chalasani NP, Sanyal AJ, Kowdley KV , et al; NASH CRN Research Group. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30 (1) 88-96
- 24 Larson SP, Bowers SP, Palekar NA, Ward JA, Pulcini JP, Harrison SA. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. Clin Gastroenterol Hepatol 2007; 5 (11) 1329-1332
- 25 Mattar SGMDF, Velcu LMMD, Rabinovitz MMD , et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242 (4) 610-617 , discussion 618–620
- 26 Vuppalanchi R, Unalp A, Van Natta ML , et al. Effects of liver biopsy sample length and number of readings on histologic yield for nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 481-486
- 27 Rousselet M-C, Michalak S, Dupré F , et al; Hepatitis Network 49. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41 (2) 257-264
- 28 Goodman ZD, Stoddard AM, Bonkovsky HL , et al; HALT-C Trial Group. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009; 50 (6) 1738-1749
- 29 Fontana RJ, Goodman ZD, Dienstag JL , et al; HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47 (3) 789-798
- 30 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
- 31 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94 (9) 2467-2474
- 32 Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31 (1) 241-246
- 33 Knodell RG, Ishak KG, Black WC , et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1 (5) 431-435
- 34 Brunt EM, Kleiner DE, Wilson L , et al. The NAS and the histopathologic diagnosis of NASH: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820
- 35 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (4) 1072-1078
- 36 Ramalho RM, Cortez-Pinto H, Castro RE , et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006; 18 (1) 21-29
- 37 Ribeiro PS, Cortez-Pinto H, Solá S , et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99 (9) 1708-1717
- 38 Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44 (1) 27-33
- 39 Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006; 23 (3–4) 149-160
- 40 Brunt EM, Ramrakhiani S, Cordes BG , et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16 (1) 49-56
- 41 Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 2002; 16 (5) 767-781
- 42 Sanyal AJ, Contos MJ, Sterling RK , et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98 (9) 2064-2071
- 43 Younossi ZM, Stepanova M, Afendy M , et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9 (6) 524-530 , e1, quiz e60
- 44 Bedossa P, Moucari R, Chelbi E , et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007; 46 (2) 380-387
- 45 Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113 (1) 40-55
- 46 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38 (4) 1008-1017
- 47 Marceau P, Biron S, Hould FS , et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84 (5) 1513-1517
- 48 Promrat K, Lutchman G, Uwaifo GI , et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39 (1) 188-196
- 49 Brunt EM, Kleiner DE, Wilson LA , et al; NASH Clinical Research Network. A list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49 (3) 809-820
- 50 Wong VW-S, Wong GL-H, Choi PC-L , et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59 (7) 969-974
- 51 Monajemi H, Stroes E, Hegele RA, Fliers E. Inherited lipodystrophies and the metabolic syndrome. Clin Endocrinol (Oxf) 2007; 67 (4) 479-484
- 52 Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol 2010; 207 (3) 245-255
- 53 Javor ED, Ghany MG, Cochran EK , et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41 (4) 753-760
- 54 Lüdtke A, Genschel J, Brabant G , et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol 2005; 100 (10) 2218-2224
- 55 Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989; 97 (4) 1022-1024
- 56 Harbour JR, Rosenthal P, Smuckler EA. Ultrastructural abnormalities of the liver in total lipodystrophy. Hum Pathol 1981; 12 (9) 856-862
- 57 de Craemer D, Van Maldergem L, Roels F. Hepatic ultrastructure in congenital total lipodystrophy with special reference to peroxisomes. Ultrastruct Pathol 1992; 16 (3) 307-316
- 58 Bodasing N, Fox R. HIV-associated lipodystrophy syndrome: description and pathogenesis. J Infect 2003; 46 (3) 149-154
- 59 Dolce CJ, Russo M, Keller JE , et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis 2009; 5 (3) 323-328
- 60 Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40 (2) 475-483
- 61 Kallwitz ER, Guzman G, TenCate V , et al. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol 2009; 104 (1) 64-69
- 62 Merriman RB, Ferrell LD, Patti MG , et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44 (4) 874-880